Proteins and Peptides
17 December 2024
LIB Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults with Elevated LDL-Cholesterol14 December 2024
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification11 December 2024
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity11 December 2024
Huonslab Announces Enrollment and Administration of First Patient in Phase 1 Pivotal Study for Hydizyme™ (rHuPH20)9 December 2024
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients6 December 2024
Simcha Therapeutics Announces the Opening of Two Clinical Studies Exploring ST-067 in Hematological Indications28 November 2024
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity28 November 2024
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment15 November 2024
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet’s Disease9 November 2024
Radella Pharmaceuticals Announces Topline Data from the Phase 1a Study of MD-18, a First-In-Class Peptide Targeting PTP1B for Obesity6 November 2024
Hanmi Unveils Novel Obesity Drug ‘HM17321’ : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss4 November 2024
Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 DiabetesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports